Literature DB >> 659609

Failure of hypoxic pulmonary vasoconstriction in the canine asthma model. Effect of prostaglandin inhibitors.

M A Cohn, H Baier, A Wanner.   

Abstract

Measurements of respiratory mechanics, arterial blood gases, and pulmonary vascular resistance were made before and 15 min after inhalation challenge with Ascaris suum extract in dogs with natural sensitivity to this antigen. 25 of 47 dogs were treated before inhalation challenge with a prostaglandin inhibitor (90 mg/kg of aspirin or 2 mg/kg of indomethacin by intravenous infusion). In response to the challenge, bronchospasm developed in approximately half (responders) of each group reflected by decreases in mean specific respiratory system conductance and arterial oxygen tension. While the dogs were breathing room air, pulmonary vascular resistance remained unchanged after antigen challenge in the responders not given aspirin or indomethacin, but increased significantly and was associated with a lesser degree of arterial hypoxemia in the responders pretreated with either of the prostaglandin inhibitors. Prevention of arterial hypoxemia by oxygen breathing blocked an increase in pulmonary vascular resistance in four pretreated responders. No changes in respiratory mechanics, pulmonary hemodynamics, or arterial blood gases were noted in the 21 dogs who did not develop bronchospasm regardless of whether or not they were pretreated. 12 additional dogs in whom arterial hypoxemia was produced by 10% oxygen breathing, showed an increase in pulmonary vascular resistance that was not potentiated by pretreatment with aspirin in 6. We conclude that in acute experimental canine asthma, vasodilator prostaglandins appear to blunt the hypoxic pulmonary vasoconstrictor response, thereby further compromising gas exchange but preventing the development of pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 659609      PMCID: PMC372672          DOI: 10.1172/JCI109066

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  OUTPUT CHARACTERISTICS OF SEVERAL COMMERCIAL NEBULIZERS.

Authors:  T T MERCER; R F GODDARD; R L FLORES
Journal:  Ann Allergy       Date:  1965-07

2.  Influence of state of inflation of the lung on pulmonary vascular resistance.

Authors:  J L WHITTENBERGER; M McGREGOR; E BERGLUND; H G BORST
Journal:  J Appl Physiol       Date:  1960-09       Impact factor: 3.531

3.  Potentiation of pulmonary vasoconstrictor response with repeated intermittent hypoxia.

Authors:  M Unger; M Atkins; W A Briscoe; T K King
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1977-10

4.  Prostaglandin synthesis inhibition restores hypoxic pulmonary vasoconstriction.

Authors:  J M Alexander; M D Nyby; K A Jasberg
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1977-06

5.  The site of pulmonary vasomotor activity during hypoxia or serotonin administration.

Authors:  M A Sackner; D H Will; A B DuBois
Journal:  J Clin Invest       Date:  1966-01       Impact factor: 14.808

Review 6.  Vascular smooth muscle and prostaglandins.

Authors:  B M Altura; B T Altura
Journal:  Fed Proc       Date:  1976-10

7.  Prostaglandin synthetase inhibitors do not decrease hypoxic pulmonary vasoconstriction.

Authors:  E K Weir; I F McMurtry; A Tucker; J T Reeves; R F Grover
Journal:  J Appl Physiol       Date:  1976-11       Impact factor: 3.531

Review 8.  Prostaglandins and local circulatory control.

Authors:  E J Messina; R Weiner; G Kaley
Journal:  Fed Proc       Date:  1976-10

9.  Study of the pulmonary circulation in a canine asthma model.

Authors:  A Wanner; M Friedman; H Baier
Journal:  Am Rev Respir Dis       Date:  1977-02

10.  Prostaglandins and aspirin therapy in Bartter's syndrome.

Authors:  L Norby; W Flamenbaum; R Lentz; P Ramwell
Journal:  Lancet       Date:  1976-09-18       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.